Backed by Bob Langer, former Harvard prof sets out to test a new way to deliver I/O drugs — during surgery
Every year, millions of cancer patients undergo surgery to get their tumors removed. But while resection can stave off cancer for some time, as many as 40% of patients would eventually see their cancer return — and succumb to the disease.
Among them were Michael Goldberg’s friends. And he does not find it acceptable.
Having trained with Bob Langer and Phillip Sharp at MIT for his PhD and postdoc, Goldberg left a faculty position at Harvard four years ago to launch Surge Therapeutics based on his lab’s work on a hydrogel tech that can be injected directly into the tumor site post-resection.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
